# A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

> **NCT05556616** · PHASE1 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D LLC** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Modakafusp alfa
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Carfilzomib
- **DRUG:** Daratumumab
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT05556616
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-12
- **Primary completion:** 2024-06-04
- **Final completion:** 2024-06-04
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Due to strategic reasons (no safety concerns).
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05556616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05556616, "A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05556616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*